Evotec SE (EVOTF)

Market Cap	1.43B
Revenue (ttm)	851.94M
Net Income (ttm)	-223.72M
Shares Out	n/a
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	902
Average Volume	826
Open	8.52
Previous Close	8.58
Day's Range	8.52 - 8.52
52-Week Range	5.98 - 12.60
Beta	1.09
RSI	38.89
Earnings Date	Aug 13, 2025

About Singular Genomics Systems

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,740
• Stock Exchange: OTCMKTS
• Ticker Symbol: EVOTF

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.